L-Homoarginine hydrochloride
Need Assistance?
  • US & Canada:
    +
  • UK: +

L-Homoarginine hydrochloride

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

L-Homoarginine is an alkaline phosphatase inhibitor found in blood, cerebrospinal fluid (CSF), and urine, as well as in human intestine and testes tissues. L-Homoarginine also acts as a substrate of CAT1, CAT2A and CAT2B, and CAT1 is a key site with regard to physiological relevance and interactions with related substrates such as L-arginine.

Category
L-Amino Acids
Catalog number
BAT-008111
CAS number
1483-01-8
Molecular Formula
C7H16N4O2·HCl
Molecular Weight
224.7
L-Homoarginine hydrochloride
IUPAC Name
(2S)-2-amino-6-(diaminomethylideneamino)hexanoic acid;hydrochloride
Synonyms
NSC 145416; (S)-2-Amino-6-guanidinohexanoic acid hydrochloride
Related CAS
156-86-5 (free base)
Appearance
White powder
Purity
≥95%
Density
1.39 g/cm3
Melting Point
207-209°C
Boiling Point
414.1°C at 760 mmHg
Storage
Store at-20 °C
Solubility
Soluble in Aqueous Acid, Water
InChI
InChI=1S/C7H16N4O2.ClH/c8-5(6(12)13)3-1-2-4-11-7(9)10;/h5H,1-4,8H2,(H,12,13)(H4,9,10,11);1H/t5-;/m0./s1
InChI Key
YMKBVNVCKUYUDM-JEDNCBNOSA-N
Canonical SMILES
C(CCN=C(N)N)CC(C(=O)O)N.Cl

L-Homoarginine hydrochloride is an amino acid derivative that plays a vital role in various biological processes. It is structurally similar to L-arginine, with an additional methylene group in its side chain. L-Homoarginine hydrochloride has gained interest due to its physiological effects, particularly its involvement in nitric oxide synthesis and cardiovascular health. The compound is available in its hydrochloride form to enhance stability and solubility, making it easier to incorporate into biological and industrial applications. Its potential therapeutic benefits have sparked research into its roles in disease prevention and management.

One key industrial application of L-homoarginine hydrochloride is in the pharmaceutical industry. Due to its influence on nitric oxide production, it is being explored for its potential to treat cardiovascular diseases. Nitric oxide is crucial for regulating blood pressure and vascular function, making L-homoarginine hydrochloride an attractive candidate for therapies aimed at hypertension, atherosclerosis, and other heart-related conditions. Its role as a nitric oxide precursor has driven research into developing drugs that target endothelial dysfunction.

Another major application is in biochemical research, where L-homoarginine hydrochloride is used as a research tool to study enzyme activity, particularly enzymes involved in nitric oxide synthesis like nitric oxide synthase (NOS). Researchers utilize L-homoarginine hydrochloride in various assays to investigate metabolic pathways and understand how modifications in amino acid structure can influence enzyme function. This helps in drug discovery and designing novel therapeutics for diseases associated with enzyme regulation.

L-homoarginine hydrochloride also finds applications in nutritional supplements due to its potential health benefits. Some studies suggest that supplementation with L-homoarginine could improve vascular health and enhance athletic performance by increasing nitric oxide levels, leading to better blood flow and endurance. As such, it is sometimes incorporated into formulations aimed at cardiovascular health or performance enhancement, although more research is required to establish these benefits fully.

Finally, L-homoarginine hydrochloride is used in the chemical synthesis industry as a precursor or intermediate in the synthesis of various bioactive compounds. Its unique structure makes it useful for producing derivatives that can be employed in pharmaceutical development or as chemical probes in research. The versatility of L-homoarginine hydrochloride in synthetic pathways adds to its value across multiple industries, particularly where the synthesis of complex molecules is required.

1. Interactions between L-arginine/L-arginine derivatives and lysozyme and implications to their inhibition effects on protein aggregation
Xiao-Yan Dong, Ming-Tao Gao, Yan Sun Biotechnol Prog . 2013 Sep-Oct;29(5):1316-24. doi: 10.1002/btpr.1766.
L-arginine (Arg), L-homoarginine (HArg), L-arginine ethylester (ArgEE), and L-arginine methylester (ArgME) were found effective in inhibiting protein aggregation, but the molecular mechanisms are not clear. Herein, stopped-flow fluorescence spectroscopy, isothermal titration calorimetry, and mass spectroscopy were used to investigate the folding kinetics of lysozyme and the interactions of the additives with lysozyme. It was found that the interactions of ArgME and ArgEE with lysozyme were similar to that of guanidine hydrochloride and were much stronger than those of Arg and HArg. The binding forces were all mainly hydrogen bonding and cation-π interaction from the guanidinium group, but their differences in molecular states led to the significantly different binding strengths. The additives formed molecular clusters in an increasing order of ArgEE, ArgME, HArg, and Arg. Arg and HArg mainly formed annular clusters with head-to-tail bonding, while ArgME and ArgEE formed linear clusters with guanidinium groups stacking. The interactions between the additives and lysozyme were positively related to the monomer contents. That is, the monomers were the primary species that participated in the direct interactions due to their intact guanidinium groups and small sizes, while the clusters performed as barriers to crowd out the protein-protein interactions for aggregation. Thus, it is concluded that the effects of Arg and its derivatives on protein aggregation stemmed from the direct interactions by the monomers and the crowding effects by the clusters. Interplay of the two effects led to the differences in their inhibition effects on protein aggregation.
2. Metabolism and distribution of pharmacological homoarginine in plasma and main organs of the anesthetized rat
Duygu Naile Günes, Arslan Arinc Kayacelebi, Joel Lundgren, Erik Hanff, Björn Redfors, Dimitrios Tsikas Amino Acids . 2017 Dec;49(12):2033-2044. doi: 10.1007/s00726-017-2465-7.
L-Homoarginine (hArg) and guanidinoacetate (GAA) are produced from L-arginine (Arg) by the catalytic action of arginine:glycine amidinotransferase. Guanidinoacetate methyltransferase methylates GAA on its non-guanidine N atom to produce creatine. Arg and hArg are converted by nitric oxide synthase (NOS) to nitric oxide (NO). NO is oxidized to nitrite and nitrate which circulate in the blood and are excreted in the urine. Asymmetric dimethylarginine (ADMA), an NOS inhibitor, is widely accepted to be exclusively produced after asymmetric NG-methylation of Arg residues in proteins and their regular proteolysis. Low circulating and urinary hArg concentrations and high circulating concentrations of ADMA emerged as risk markers in the human renal and cardiovascular systems. While ADMA's distribution and metabolism are thoroughly investigated, such studies on hArg are sparse. The aim of the present pilot study was to investigate the distribution of exogenous hArg in plasma, liver, kidney, lung, and heart in a rat model of takotsubo cardiomyopathy (TTC). hArg hydrochloride solutions in physiological saline were injected intra-peritoneally at potentially pharmacological, non-toxic doses of 20, 220, or 440 mg/kg body weight. Vehicle (saline) served as control. As hArg has been reported to be a pro-oxidant, plasma and tissue malondialdehyde (MDA) was measured as a biomarker of lipid peroxidation. hArg administration resulted in dose-dependent maximum plasma hArg concentrations and distribution in all investigated organs. hArg disappeared from plasma with an elimination half-life ranging between 20 and 40 min. hArg administration resulted in relatively small changes in the plasma and tissue content of Arg, GAA, ADMA, creatinine, and of the NO metabolites nitrite and nitrate. Remarkable changes were observed for tissue GAA, notably in the kidney. Plasma and tissue MDA concentration did not change upon hArg administration, suggesting that even high-dosed hArg is not an oxidant. The lowest hArg dose of 20 mg/kg bodyweight increased 25-fold the mean hArg maximum plasma concentration. This hArg dose seems to be useful as the upper limit in forthcoming studies on the putative cardioprotective effects of hArg in our rat model of TTC.
3. Nitric oxide regulates IL-8 expression in melanoma cells at the transcriptional level
I J Lindley, H Harant, P J Andrew Biochem Biophys Res Commun . 1995 Sep 25;214(3):949-56. doi: 10.1006/bbrc.1995.2378.
We investigated the role of nitric oxide (NO) in the expression of interleukin-8 (IL-8) in the human melanoma cell line, G361. Three NO donors, 3-morpholinosydnonimine hydrochloride (SIN-1), S-nitroso-N-acetylpenicillamine (SNAP), and S-nitroso-L-glutathione (SNOG), all caused an increase in both IL-8 protein secretion and promoter activity. Truncation of the promoter showed that 101 bp of the 5' flanking region proximal to the transcription start site are sufficient for the response to NO. Furthermore, mutation of the NF-kappa B and NF-IL-6 binding sites led to a significant decrease in NO-stimulated promoter activity. The nitric oxide synthase inhibitor, NG-amino-L-homoarginine (NAHA), inhibited TNF-alpha-stimulated IL-8 promoter activity by 60%. Addition of excess L- but not D-arginine partially reversed the NAHA-mediated inhibition. These results demonstrate that NO is an endogenous regulator of IL-8 production in G361 melanoma cells.
Online Inquiry
Verification code
Inquiry Basket